The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the first generic raltegravir drug to treat adult and paediatric HIV patients who weigh at least 40kg. HIV produces an enzyme called HIV integrase which enables multiplication of the virus in cells within the body. Raltegravir stops this enzyme from working, and when used […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!